Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
is a cyclooxygenase-2 inhibitor used to treat osteoarthritis
Smiles: CC1C(N)=NC(=NC=1C(=O)N[C@@H]([C@@H](O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](OC(N)=O)[C@@H]1O)C1=CN=CN1)C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O
Smiles: CC1=CN=C(C=N1)NC(=O)NC1=CC(Br)=C(C)C=C1OC[C@@H]1CNCCO1
Formula: C6H6O6
InChi: InChI=1S/C26H27NO5/c27-11-12-29-13-14-30-15-16-31-18-19-5-7-21(8-6-19)25-17-23(28)26-22-4-2-1-3-20(22)9-10-24(26)32-25/h1-10
MK-0354 497 is a cyclooxygenase-2 inhibitor usedMK 0354 is a partial agonist of GPR109a receptor, for hGPR109a mGPR109a with EC50 of 1. 65 1. 08 M, showed no activation of GPR109b. IC50 value: 1. 65 M (EC50, for hGPR109a), 1. 08 M (EC50, for mGPR109a) Target: GPR109ain vitro: MK 0354 demonstrated clear and statistically significant partial agonism in the cAMP assays for both the mouse and human receptors with efficacy approximately 60 70% of that of either nicotinic acid or hydroxy butyrate, a
US$ 1384.50
US$ 45.00
US$ 24.00
US$ 84.99
US$ 33.00
US$ 45.00
US$ 1289.50
US$ 29.99